DANIEL ERNESTO
CASTELLANO GAUNA
Profesor asociado de Ciencias de la Salud
Erasmus University Medical Center
Róterdam, HolandaPublicacions en col·laboració amb investigadors/es de Erasmus University Medical Center (10)
2021
-
Baseline neutrophil-to-lymphocyte ratio as a predictive and prognostic biomarker in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel versus abiraterone or enzalutamide in the CARD study
ESMO Open, Vol. 6, Núm. 5
-
Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: Post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive disease
Japanese Journal of Clinical Oncology, Vol. 51, Núm. 8, pp. 1287-1297
-
Efficacy and Safety of Cabazitaxel Versus Abiraterone or Enzalutamide in Older Patients with Metastatic Castration-resistant Prostate Cancer in the CARD Study
European Urology, Vol. 80, Núm. 4, pp. 497-506
2020
-
Cabazitaxel in Metastatic Prostate Cancer. Reply
The New England journal of medicine
-
Cabazitaxel in metastatic prostate cancer
New England Journal of Medicine
-
Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
European Urology
-
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort†[Formula presented]: Under the Auspices of the EAU-ESMO Guidelines Committees
European Urology, Vol. 77, Núm. 2, pp. 223-250
-
Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study
The Lancet Oncology, Vol. 21, Núm. 11, pp. 1513-1525
2019
-
Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer
New England Journal of Medicine, Vol. 381, Núm. 26, pp. 2506-2518
-
EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
Annals of Oncology, Vol. 30, Núm. 11, pp. 1697-1727